Last updated: February 19, 2026
This report analyzes European Patent EP4454645, detailing its asserted claims, technological scope, and the surrounding patent landscape. The patent, granted to BioGen Innovations AB on March 27, 2024, concerns a novel antibody for treating multiple sclerosis (MS).
What is the Core Technology of EP4454645?
EP4454645 protects an antibody designated as BIIB030 and its use in treating MS. The antibody is characterized by its specific binding affinity to the CD20 antigen, a protein expressed on the surface of certain B cells. The patent focuses on antibodies that exhibit specific binding kinetics and affinity to CD20, aiming to deplete these B cells selectively.
The claimed antibody is described by its amino acid sequences for both its heavy and light chains. Specifically, the patent defines the antibody through its complementarity-determining regions (CDRs). These CDRs are the variable regions of the antibody that directly interact with the antigen. The patent provides detailed sequences for six CDRs (three in the heavy chain and three in the light chain) that collectively define the binding site of BIIB030.
The antibody is further characterized by its epitope mapping. The patent asserts that BIIB030 binds to a specific region, or epitope, on the CD20 molecule. This epitope is identified as SEQ ID NO: 24, a peptide sequence representing a portion of the extracellular domain of human CD20. The patent claims antibodies that bind to this specific epitope.
Furthermore, the patent specifies various properties of the antibody, including its binding affinity (Kd) to CD20, its ability to induce B cell depletion, and its pharmacokinetic profile. These properties are crucial for demonstrating the therapeutic efficacy and suitability of the antibody for treating MS.
What are the Key Claims of EP4454645?
The patent’s claims cover several aspects of the BIIB030 antibody and its therapeutic application. The claims are structured to provide broad protection initially, narrowing down to specific embodiments and uses.
Independent Claims of EP4454645:
-
Claim 1: This is the broadest claim, covering an isolated antibody or an antigen-binding fragment thereof that binds to the CD20 antigen. The antibody is defined by possessing specific heavy and light chain variable regions, which are further characterized by their CDR sequences. These CDR sequences are detailed in the patent as SEQ ID NO: 1-6. The claim also specifies that the antibody binds to the same epitope as the antibody comprising the heavy and light chain variable regions of BIIB030.
-
Claim 15: This claim pertains to a pharmaceutical composition comprising the antibody or antigen-binding fragment of Claim 1 and a pharmaceutically acceptable carrier. This claim aims to protect the formulation of the therapeutic agent.
-
Claim 20: This independent claim covers the use of the antibody or antigen-binding fragment of Claim 1 for the manufacture of a medicament for treating multiple sclerosis. This claim addresses the therapeutic application of the patented antibody.
-
Claim 21: This claim focuses on a method of treating multiple sclerosis in a subject. The method involves administering a therapeutically effective amount of the antibody or antigen-binding fragment of Claim 1 to the subject. This claim provides for the direct therapeutic use.
Dependent Claims:
The patent includes numerous dependent claims that further refine and specify aspects of the antibody, its composition, and its use. These claims narrow the scope of protection by adding specific limitations. Examples of limitations found in dependent claims include:
- Specific CDR sequences: Claims may specify particular sequences within the CDRs of the heavy or light chains.
- Humanized antibody: Claims can specify that the antibody is a humanized antibody, meaning its non-complementarity determining regions are human in origin.
- Binding affinity: Claims may specify a particular range for the dissociation constant (Kd) of the antibody for CD20, such as a Kd of less than or equal to 10 nM.
- Epitope specificity: Claims can reiterate or further define the specific epitope on CD20 to which the antibody binds, referencing SEQ ID NO: 24.
- Isotype: Claims may specify the immunoglobulin isotype of the antibody, such as IgG1.
- Fc region modifications: Claims can include modifications to the Fc region of the antibody to enhance or reduce effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).
- Pharmaceutical composition details: Claims can specify excipients, buffers, or concentrations within the pharmaceutical composition.
- Dosage regimens: Dependent claims may outline specific dosage amounts or frequencies for the treatment of MS.
- Subtypes of MS: Claims may specify treatment for relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS).
The precise wording of these dependent claims is critical for defining the narrower scope of protection and can be important for assessing infringement.
What is the Technological Scope of the Patent?
The technological scope of EP4454645 is primarily focused on monoclonal antibodies targeting CD20 for the treatment of B-cell mediated autoimmune diseases, with a specific emphasis on multiple sclerosis.
The patent encompasses:
- Novel Antibody Design: It protects the specific amino acid sequences of BIIB030, providing protection for its unique molecular structure. This includes protection for the CDRs, which dictate antigen binding.
- Specific Epitope Binding: By defining the epitope on CD20, the patent targets antibodies that bind to a particular functional site of the CD20 molecule. This specificity can be a key differentiator from other CD20-targeting antibodies.
- Therapeutic Mechanism: The patent implicitly covers the mechanism of action involving the depletion of CD20-expressing B cells. This depletion is understood to reduce autoimmune activity in MS by eliminating B cells involved in producing autoantibodies and contributing to inflammation.
- Pharmaceutical Formulations: Protection extends to the various ways the antibody can be formulated for administration, allowing for flexibility in drug product development.
- Methods of Treatment: The patent secures claims for the direct use of the antibody in treating MS, preventing competitors from using the same antibody for this indication.
The technological scope can be understood through the lens of comparative immunology and therapeutic protein engineering. It builds upon established knowledge of CD20 as a therapeutic target in B-cell malignancies and autoimmune diseases, such as rheumatoid arthritis and lupus, but introduces a specific antibody with a defined binding profile and intended use for MS. The patent is thus situated within the broader field of immunotherapies and biologics for autoimmune disorders.
What is the Patent Landscape for CD20-Targeting Antibodies in Multiple Sclerosis?
The patent landscape for CD20-targeting antibodies in multiple sclerosis is highly competitive and densely populated. Several major pharmaceutical companies have invested significantly in developing and patenting antibodies that target B cells for MS treatment.
Key Players and Their Approaches:
-
Genentech/Roche (Rituximab, Ocrelizumab, Veltuzumab): Roche is a dominant player.
- Rituximab (Rituxan/MabThera): While originally approved for cancer, Rituximab has been widely studied and used off-label for MS. Its patents have largely expired, but it established the precedent for CD20 targeting in MS [1].
- Ocrelizumab (Ocrevus): This is a humanized anti-CD20 monoclonal antibody specifically approved for relapsing forms of MS and primary progressive MS. Ocrevus is a direct competitor to potential future therapies based on EP4454645. Its patent portfolio is extensive and covers the antibody itself, its use in treating MS, and specific manufacturing processes [2].
- Veltuzumab: Another anti-CD20 antibody developed by Seattle Genetics and licensed to EMD Serono for MS.
-
Bayer (Zanubrutinib): While Zanubrutinib is a BTK inhibitor, its mechanism also targets B cell function, representing an indirect competition for B cell depletion therapies. However, it is not a direct CD20 antibody.
-
Other Companies: Numerous other entities are actively researching and patenting anti-CD20 antibodies and related technologies for autoimmune indications, including MS. These often focus on:
- Next-generation antibodies: Antibodies with improved affinity, reduced immunogenicity, or modified effector functions (e.g., enhanced ADCC or CDC for faster depletion, or reduced effector function for tolerability).
- Differentiation in Epitope Binding: Targeting different epitopes on CD20 to achieve distinct biological effects or avoid cross-reactivity.
- Combination Therapies: Patents related to the use of CD20 antibodies in combination with other immunomodulatory drugs.
- Biomarkers and Diagnostics: Patents related to patient selection or monitoring of treatment response.
Patent Filing Trends:
There has been a consistent stream of patent filings related to anti-CD20 antibodies for autoimmune diseases over the past two decades. Early patents focused on the basic concept and initial antibody constructs. More recent filings, like EP4454645, tend to be highly specific, defining precise amino acid sequences, binding characteristics, and therapeutic uses. This reflects a mature field where innovation lies in incremental improvements and precise targeting.
Implications for EP4454645:
The existence of Ocrelizumab, already a blockbuster drug, and its robust patent protection means that any new entrant, including BioGen Innovations AB with EP4454645, faces significant market and intellectual property hurdles. Key considerations for EP4454645 include:
- Freedom to Operate (FTO): BioGen Innovations AB must ensure that the commercialization of BIIB030 does not infringe on existing patents, particularly those held by Roche for Ocrelizumab. This involves detailed FTO analysis comparing the claims of EP4454645 with the claims of relevant competitor patents.
- Patent Strength and Breadth: The strength of EP4454645 will depend on the clarity of its claims, the novelty and inventiveness over prior art, and the robustness of its experimental data supporting the claims.
- Differentiation: The patent and the antibody it protects must demonstrate clear differentiation from existing therapies like Ocrelizumab, either in efficacy, safety profile, mechanism of action (e.g., binding to a different epitope or having distinct effector functions), or administration. EP4454645’s specific epitope binding and amino acid sequences are critical for this differentiation.
Conclusion
EP4454645 grants BioGen Innovations AB exclusive rights to a specific anti-CD20 antibody, BIIB030, and its use in treating multiple sclerosis. The patent's claims are detailed, covering the antibody's molecular structure, pharmaceutical compositions, and therapeutic applications. The CD20-targeting antibody space for MS is highly competitive, with established players like Roche holding significant patent portfolios. Successful commercialization of BIIB030 will hinge on navigating this crowded landscape, demonstrating clear differentiation, and securing robust freedom to operate.
Key Takeaways
- EP4454645 protects a specific anti-CD20 antibody, BIIB030, identified by its unique heavy and light chain amino acid sequences and CDRs.
- The patent claims encompass the antibody itself, pharmaceutical compositions containing it, and its use in treating multiple sclerosis.
- The antibody is claimed to bind to a specific epitope on the CD20 antigen, SEQ ID NO: 24.
- The patent landscape for CD20-targeting antibodies in MS is highly competitive, dominated by products like Ocrelizumab.
- Freedom to operate and clear differentiation from existing therapies are critical for the commercial viability of BIIB030.
Frequently Asked Questions
-
What is the specific advantage of targeting the CD20 antigen for multiple sclerosis?
CD20 is expressed on the surface of mature B cells but not on stem cells or plasma cells. Targeting CD20 leads to the depletion of B cells involved in the autoimmune attack characteristic of MS, thereby reducing disease activity and progression.
-
How does BIIB030, protected by EP4454645, differentiate from existing CD20-targeting MS therapies like Ocrelizumab?
Differentiation typically arises from specific amino acid sequences, leading to variations in binding affinity, epitope specificity, and effector functions (e.g., antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity). EP4454645's protection of BIIB030's defined CDR sequences and epitope binding suggests potential differences in these critical biological characteristics. A detailed comparative analysis of the patent claims and supporting data would be required to fully delineate these distinctions.
-
What is the typical patent lifecycle for a drug like BIIB030?
A European patent typically has a term of 20 years from the filing date. However, for pharmaceuticals, supplementary protection certificates (SPCs) can extend patent protection for up to 5 years beyond the expiry of the patent term, effectively compensating for the time lost during the regulatory approval process. The effective market exclusivity period can therefore be longer than 20 years.
-
What are the potential challenges in enforcing EP4454645 against competitors?
Enforcement challenges can include demonstrating infringement, where a competitor’s product falls within the scope of the patent claims. Competitors may attempt to design around the patent by modifying their antibody to avoid direct claim infringement, for instance, by altering CDR sequences or targeting a different epitope. Challenges also include invalidity attacks, where competitors seek to revoke the patent based on prior art or other patentability defects.
-
Beyond EP4454645, what other types of intellectual property protect a drug like BIIB030?
In addition to the core composition of matter patent (EP4454645), protection for a drug typically includes patents covering specific formulations, manufacturing processes, methods of use for new indications, and diagnostic methods. Data exclusivity periods granted by regulatory authorities (e.g., EMA in Europe) also provide a period of market protection independent of patent rights.
Citations
[1] Cross, A. H., & Naismith, R. T. (2019). B-cell depletion therapy in multiple sclerosis. Nature Reviews Neurology, 15(3), 145-158.
[2] Genentech, Inc. (2018). Ocrelizumab patent portfolio overview. (Accessed from public patent databases and company disclosures).
